CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点抑制剂（ICI）已成为肾细胞癌（RCC）转移性疾病和辅助治疗的基石。然而，癌细胞可能在 ICI 治疗过程中产生适应性耐药，因此许多研究正关注其他免疫检查点通路。正在研究的有前景免疫治疗靶点包括 T 细胞免疫球蛋白和 ITIM 结构域蛋白（TIGIT）、免疫球蛋白样转录物 4（ILT4）、淋巴细胞活化基因 3（LAG-3）、疫苗、T 细胞免疫球蛋白和黏蛋白结构域蛋白 3（TIM-3）以及嵌合抗原受体（CAR）T 细胞。本综述汇总 RCC 免疫治疗领域正在研究的新型治疗策略现有知识，并分析其作用机制、活性及当前正在开展的临床研究。
Immune checkpoint inhibitors (ICI) have become the cornerstone of treatment in renal cell carcinoma (RCC), for both metastatic disease and in an adjuvant setting.
However, an adaptive resistance from cancer cells may arise during ICI treatment, therefore many studies are focusing on additional immune checkpoint inhibitor pathways. Promising targets of immunotherapeutic agents under investigation include T cell immunoglobulin and ITIM domain (TIGIT), immunoglobulin-like transcript 4 (ILT4), lymphocyte activation gene-3 (LAG-3), vaccines, T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and chimeric antigen receptor (CAR) T cells.
In this review of the literature, we recollect the current knowledge of the novel treatment strategies in the field of immunotherapy that are being investigated in RCC and analyze their mechanism of action, their activity and the clinical studies that are currently underway.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
